Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 68.08B 9.11B 8.62B 7.83B 14.63B 1,001B 14.7B 103B 39.7B 509B 39.28B 38.4B 1,629B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 68.28B 9.13B 8.64B 7.85B 14.67B 1,004B 14.74B 103B 39.81B 510B 39.39B 38.51B 1,634B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
25/04/21	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/02/20	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/02/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
13/01/20	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/11/19	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
24/11/19	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/11/19	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/11/19	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/10/19	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/06/21	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/02/20	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/01/20	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Share Price

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	12/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	29/02/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK & CO., INC.	+1.55%	+1.69%	+81.35%	+36.86%	363B
MERCK KGAA	+0.21%	+0.15%	+22.52%	-18.13%	65.62B
HALOZYME THERAPEUTICS, INC.	+1.14%	+2.50%	+44.68%	+179.65%	12.45B
KYOWA KIRIN CO., LTD.	-0.29%	+2.94%	-6.00%	-16.51%	7.6B
SK BIOPHARMACEUTICALS CO., LTD.	+1.28%	-5.04%	-26.26%	-13.25%	4.49B
YUHAN CORPORATION	+0.26%	-1.77%	-33.30%	+7.78%	4.19B
BETTA PHARMACEUTICALS CO., LTD.	-1.48%	+0.87%	-32.20%	-15.17%	2.92B
SUPERNUS PHARMACEUTICALS, INC.	+3.72%	+2.95%	-4.20%	+46.84%	2.49B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.77%	-0.30%	-27.96%	-33.50%	1.93B
Average	+0.56%	+1.06%	+2.07%	+19.40%	46.64B
Weighted average by Cap.	+1.28%	+1.41%	+66.94%	+30.73%

	2017	2018
Net sales	30.17M 196M 26.28M 24.87M 22.59M 42.21M 2.89B 42.42M 296M 115M 1.47B 113M 111M 4.7B	39.49M 257M 34.4M 32.56M 29.58M 55.26M 3.78B 55.53M 388M 150M 1.92B 148M 145M 6.15B
Net income	-9.54M -62.13M -8.31M -7.87M -7.15M -13.35M -914M -13.42M -93.69M -36.23M -464M -35.85M -35.05M -1.49B	-5.28M -34.41M -4.6M -4.36M -3.96M -7.39M -506M -7.43M -51.89M -20.07M -257M -19.85M -19.41M -823M
Net Debt	18.05M 118M 15.72M 14.88M 13.52M 25.26M 1.73B 25.38M 177M 68.54M 879M 67.81M 66.3M 2.81B	29.38M 191M 25.59M 24.22M 22.01M 41.12M 2.81B 41.32M 289M 112M 1.43B 110M 108M 4.58B